Intellipharmaceutics International Stock Net Income
Intellipharmaceutics International fundamentals help investors to digest information that contributes to Intellipharmaceutics' financial success or failures. It also enables traders to predict the movement of Intellipharmaceutics OTC Stock. The fundamental analysis module provides a way to measure Intellipharmaceutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intellipharmaceutics otc stock.
Intellipharmaceutics |
Intellipharmaceutics International OTC Stock Net Income Analysis
Intellipharmaceutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Intellipharmaceutics Net Income | (5.15 M) |
Most of Intellipharmaceutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intellipharmaceutics International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Intellipharmaceutics International reported net income of (5.15 Million). This is 101.51% lower than that of the Pharmaceuticals sector and 107.35% lower than that of the Health Care industry. The net income for all United States stocks is 100.9% higher than that of the company.
Intellipharmaceutics Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intellipharmaceutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Intellipharmaceutics could also be used in its relative valuation, which is a method of valuing Intellipharmaceutics by comparing valuation metrics of similar companies.Intellipharmaceutics is currently under evaluation in net income category among its peers.
Intellipharmaceutics Fundamentals
| Return On Asset | -0.98 | |||
| Operating Margin | (106.06) % | |||
| Current Valuation | 4.47 M | |||
| Shares Outstanding | 33.09 M | |||
| Shares Owned By Insiders | 1.70 % | |||
| Shares Owned By Institutions | 11.09 % | |||
| Number Of Shares Shorted | 714 K | |||
| Price To Earning | (0.50) X | |||
| Price To Sales | 66.19 X | |||
| Gross Profit | 1.4 M | |||
| EBITDA | (4.45 M) | |||
| Net Income | (5.15 M) | |||
| Cash And Equivalents | 79.65 K | |||
| Total Debt | 2.01 M | |||
| Debt To Equity | 165.20 % | |||
| Current Ratio | 0.05 X | |||
| Book Value Per Share | (0.31) X | |||
| Cash Flow From Operations | (2.46 M) | |||
| Short Ratio | 0.39 X | |||
| Earnings Per Share | (0.16) X | |||
| Target Price | 25.0 | |||
| Number Of Employees | 11 | |||
| Beta | 1.0 | |||
| Market Capitalization | 2.02 M | |||
| Total Asset | 2.1 M | |||
| Retained Earnings | (86.55 M) | |||
| Working Capital | (5.62 M) | |||
| Current Asset | 1.41 M | |||
| Current Liabilities | 7.02 M | |||
| Z Score | -65.8 | |||
| Net Asset | 2.1 M |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Intellipharmaceutics OTC Stock
If you are still planning to invest in Intellipharmaceutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intellipharmaceutics' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |